#721
|
||||
|
||||
Íàëè÷èå àíåìèè ïîâûøàåò â ïîëòîðà ðàçà ðèñê ñìåðòíîñòè è âîçíèêíîâåíèÿ äð. òðîìáîòè÷åñêèõ îñëîæíåíèé ó ïàöèåíòîâ ñ ÔÏ íà ôîíå íàçíà÷åíèÿ àíòèêîàãóëÿíòîâ è â 2 ðàçà ðèñê áîëüøèõ êðîâîòå÷åíèé - äàííûå èç RE-LY:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#722
|
|||
|
|||
 Schein's common sense 'Prevention and management of Surgical complications' îáíàðóæèëà çàáàâíóþ çàìåòêó
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì |
#723
|
||||
|
||||
Êàê ïðàçîëû èëè Í2-áëîêåðû è ó êîãî ïðåäîòâðàùàþò ÆÊÊ íà ôîíå ïðèåìà äàáèãàòðàíà:
Among the 5041 patients newly prescribed dabigatran, 124 (2.5%) developed GIB during follow-up (4.2/100 patient-years). The risk of GIB in this population increased among patients 75 y old or older (IRR, 2.47; 95% confidence interval [CI], 1.66-3.68), patients with a history of peptic ulcers or GIB (IRR, 2.31; 95% CI, 1.54-3.46), and patients who used aspirin (IRR, 1.52; 95% CI, 1.03-2.24). Concomitant use of GPAs was associated with a reduced risk of GIB (IRR, 0.52; 95% CI, 0.35-0.77). Subcategory analysis showed that use of proton-pump inhibitors (IRR, 0.53; 95% CI, 0.31-0.91) or histamine type-2 receptor antagonists (IRR, 0.61; 95% CI, 0.40-0.94) were associated with lower risk of GIB. Further analysis revealed that the risk reduction by GPAs was significant for only upper GIB (IRR, 0.29; 95% CI, 0.15-0.54) and only for patients with prior history of peptic ulcers or GIB (IRR, 0.14; 95% CI, 0.06-0.30). --- Gastroenterology. 2015 May 7. Prevention of Dabigatran-related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Chan EW, è ñîàâò. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#724
|
||||
|
||||
Öèòàòà:
|
#725
|
||||
|
||||
Ëþáèòåëè íàïóñòèòü ñåáå îçîíó â êðîâü ñ çàìîëàæèâàþùåé öåëüþ ïîðîé î÷åíü è î÷åíü ðèñêóþò - íàãëÿäíûé ïðèìåð îò òóðåöêèõ êîëëåã:
Myocardial Infarction after Ozone Therapy: Is Ozone Therapy Dr. Jekyll or Mr. Hyde? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#726
|
||||
|
||||
íå âñå ïëîõî òî, ÷òî ïîâûøåíî ñâåðõíîðìû - ãèïåðáèëèðóáèíåìèÿ èç-çà ñ-ìà Æèëüáåðà ñíèæàåò îá. ñìåðòíîñòü èëè ðèñê äèàáåòà-2:
Bilirubin as a Potential Causal Factor in Type 2 Diabetes Risk: A Mendelian Randomization Study [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Gilbert's syndrome and the risk of death: a population-based cohort study. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#727
|
||||
|
||||
Íà ìîé âçãëÿä, î÷åíü èíòåðåñíûé ãàéä.
2015 Treatment of Hypertension in Patients*With Coronary Artery Disease. A Scientific Statement from the American Heart Association, American College of Cardiology, and*American Society of Hypertension. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#728
|
|||
|
|||
Íîâûå åâðîïåéñêèå ðåêîìåíäàöèè ïî non-ST ACS
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì |
#729
|
||||
|
||||
Íà ìåäñêåéïå îïóáëèêîâàëè ðåçóëüòàòû èññëåäîâàíèé ïî àíòèäîòàì ê äàáèãàòðàíó (idarucizumab_RE-VERSE AD study) è áëîêàòîðàì Xà ôàêòîðà (andexanet alfa_ANNEXA-A study). Åñëè ÿ ïðàâèëüíî ïîíÿë - êëèíè÷åñêàÿ ÷àñòü èññëåäîâàíèé åùå âïåðåäè. Îäíàêî îáùèé òðåíä ê ïåðåõîäó ñ âàðôàðèíà íà ÍÎÀÊ óêðåïëÿåòñÿ.
|
#730
|
||||
|
||||
Äà, êàê è ðàíåå ñîñòîÿëñÿ ïåðåõîä ñ îáû÷íîãî ãåïàðèíà ïîä êîíòðîëåì À×Ò íà ÍÌà ïî ìàññå òåëå âî ìíîãèõ êëèí. ñèòóàöèÿõ, õîòÿ îòäåëüíûå íèøè äëÿ êëèí. èñïîëüçîâàíèÿ îáû÷íîãî ãåïàðèíà îñòàþòñÿ... Âñòðå÷íûé âîïðîñ - êàêîâû øàíñû, ÷òî ýòè àíòèäîòû áóäóò âîñòðåáîâàíû/çàðåãèñòðèðîâàíû â ÐÔ? Íàïðèìåð, îòñóòñòâèå Äèãèáèíäà (ìîíîêëîí. ôðàãìåíòà äëÿ èíàêòèâàöèè äèãîêñèíà ïðè åãî ïåðåäîçèðîâêå) íèêàê íå îñòàíàâëèâàåò èñïîëüçîâàíèå äèãîêñèíà â êëèíè÷åñêîé ïðàêòèêå. Ïîëàãàþ, ÷òî öåíà íà ýòè àíòèäîòû áóäåò òàêàÿ, ÷òî äåøåâëå áóäåò ñïàñàòü ïàöèåíòà ïîäðó÷íûìè ãåìîñòàòè÷åñêèìè ñðåäñòâàìè, ïî ýòîé æå ïðè÷èíå ïðàêòè÷åñêè îòñóòñòâóåò îòå÷åñòâåííûé îïûò ïðèìåíåíèÿ íîâîñåâåíà ïðè êðîâîòå÷åíèÿõ, íå ñâÿçàííûõ ñ èíãèáèòîðíûìè ãåìîôèëèÿìè.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#731
|
||||
|
||||
Öåíû íà ìîíîêëîíàëüíûå ïðåïàðàòû, âèäèìî, åùå íå ñêîðî ñíèçîéäóò ñ íåáåñ íà çåìëþ. ÈÌÕÎ, ïðè çàêóïî÷íîé öåíå ~$500-1000 çà êóðñîâóþ äîçó ó íèõ ìîæåò áûòü ïåðñïåêòèâà èñïîëüçîâàíèÿ è â Ðîññèè. À ïîêà... ... ìû âèäèì òîëüêî ðîñò ïðèåìà ÍÎÀÊ ó êàðäèîëîãè÷åñêèõ ïàöèåíòîâ.
|
#732
|
||||
|
||||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#733
|
|||
|
|||
Óâàæàåìûå êîëëåãè!
Ðàä Âàñ ïðîèíôîðìèðîâàòü, ÷òî ìû ïîäãîòîâèëè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] EHRA/HRS/APHRS êîíñåíñóñíîãî äîêóìåíòà ïî æåëóäî÷êîâûì àðèòìèÿì çà 2014 ãîä. Íàäåþñü, ÷òî îí ïðèãîäèòñÿ â Âàøåé êëèíè÷åñêîé ïðàêòèêå. ÏÑ. Ðàçðåøåíèå íà ðàçìåùåíèå ýëåêòðîííîé âåðñèè ïîëó÷åíî òîëüêî äëÿ ñàéòà íàøåãî ó÷ðåæäåíèÿ. |
#734
|
||||
|
||||
Îïÿòü î êîôå: åãî ðåãóëÿðíûé ïðèåì ñíèæàåò ðèñê óìåðåòü îò ÑÑÇ, çàáîëåâàíèé ëåãêèõ è ñóèöèäà, íî íå çàùèùàåò îò ñìåðòè, âûçâàííîé îíêîçàáîëåâàíèÿìè - ýôôåêò ïîõîæå íå çàâèñèò îò êîëè÷åñòâà ñîäåðæàíèÿ êîôåèíà
Significant inverse associations were observed between coffee consumption and deaths attributed to cardiovascular disease, neurologic diseases, and suicide. No significant association between coffee consumption and total cancer mortality was found. Higher consumption of total coffee, caffeinated coffee, and decaffeinated coffee was associated with lower risk of total mortality. --- Association of Coffee Consumption With Total and Cause-Specific Mortality in 3 Large Prospective Cohorts. Circulation. 2015 Dec 15;132(24):2305-15. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] +++ Similar findings were observed for decaffeinated coffee and coffee additives. Inverse associations were observed for deaths from heart disease, chronic respiratory diseases, diabetes, pneumonia and influenza, and intentional self-harm, but not cancer. Coffee may reduce mortality risk by favorably affecting inflammation, lung function, insulin sensitivity, and depression. --- Association of Coffee Consumption With Overall and Cause-Specific Mortality in a Large US Prospective Cohort Study. Am J Epidemiol. 2015 Dec 15;182(12):1010-22. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#735
|
|||
|
|||
 2010 ã îïóáëèêîâàíî FDA äîïîëíåíèå ê ðåêîìåíäàöèè 2009 ã ïî ïðèìåíåíèþ Êëîïèäîãðåëÿ ñîâìåñòíî ñ Îìåïðàçîëîì.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ×òî èçìåíèëîñü çà ïîñëåäóþùèå ãîäû? Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] To conclude, this analysis highlights two important facts: 1) the FDA Safety Communication resulted in a reduction in the total number of patients undergoing clopidogrel-PPI combination therapy and 2) although a decrease in the proportion of patients receiving a combination with a CYP2C19 inhibitor PPI, omeprazole remained one of the PPIs most prescribed with clopidogrel. These findings are surprising considering the multitude of FDA communications, drug label changes, and clinical studies discouraging the use of such combination. |